Jump Therapeutics
At 40nM treatment concentrations, our SSO achieves significant reductions in viability compared with scrambled negative control oligonucleotide treatment in H1299 cells expressing the TE-derived LIN28B oncogene target. 40nM transfection followed by qPCR showed a ~40% reduction in LIN28B mRNA and western blot revealed a perceptible reduction in LIN28B protein expression at 40nM and 60nM compared to equal concentrations of the scrambled negative control antisense oligonucleotide.
Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on reddit
The Idea Bouncer:
- Noah Basri
- PARTNER: WashU Skandalaris Center
- PROGRAM: Global Impact Award (GIA) 2023, SVC Spring 2023
- INDUSTRY: Biotechnology, Medicine
- NEEDS: Investors, Market Analysis, Operations and Management